Key result
Elevated Lp(a) is linked to ~190% higher risk of aortic valve stenosis.
Why the study?
The etiologic basis of aortic valve stenosis is unclear, though recent data have implicated an LPA genetic variant associated with lipoprotein(a) levels.
Do elevated lipoprotein(a) levels and corresponding LPA risk genotypes increase the risk of aortic valve stenosis in the general population?
Observational (n=77,680)
Yes
Do elevated lipoprotein(a) levels and corresponding LPA risk genotypes increase the risk of aortic valve stenosis in the general population?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Kamstrup et al. confirm and extend the findings of Thanassoulis et al. by showing that elevated Lp(a) levels (>74 mg/dl, representing ∼10% to 15% of the general population) were independently associated with CAVS, predicting a 3-fold increased risk. Consistent with genetic causality, carriers of LPA SNPs rs10455872 and rs3798220 and of low number of KIV-2 repeats, all of which are associated with higher Lp(a) levels, were also associated with CAVS. The enhanced risk was driven by high Lp(a) levels and not an independent risk of the LPA SNPs.”
Elevated Lp(a) levels and corresponding genetic variants are prospectively associated with a significantly increased risk of aortic valve stenosis in the general population.
OBJECTIVES The purpose of this study was to determine whether elevated lipoprotein(a) levels and corresponding LPA risk genotypes (rs10455872, rs3798220, kringle IV type 2 repeat polymorphism) prospectively associate with increased risk of aortic valve stenosis (AVS). BACKGROUND The etiologic basis of AVS is unclear. Recent data implicate an LPA genetic variant (rs10455872), associated with Lp(a) levels, in calcific AVS. METHODS We combined data from 2 prospective general population studies, the Copenhagen City Heart Study (1991 to 2011; n = 10,803) and the Copenhagen General Population Study (2003 to 2011; n = 66,877), following up 77,680 Danish participants for as long as 20 years, during which time 454 were diagnosed with AVS. We conducted observational and genetic instrumental variable analyses in a Mendelian randomization study design. RESULTS Elevated Lp(a) levels were associated with multivariable adjusted hazard ratios for AVS of 1.2 (95% confidence interval [CI]: 0.8 to 1.7) for 22nd to 66th percentile levels (5 to 19 mg/dl), 1.6 (95% CI: 1.1 to 2.4) for 67th to 89th percentile levels (20 to 64 mg/dl), 2.0 (95% CI: 1.2 to 3.4) for 90th to 95th percentile levels (65 to 90 mg/dl), and 2.9 (95% CI: 1.8 to 4.9) for levels greater than 95th percentile (>90 mg/dl), versus levels less than the 22nd percentile (<5 mg/dl; trend, p < 0.001). Lp(a) levels were elevated among carriers of rs10455872 and rs3798220 minor alleles, and of low number of KIV-2 repeats (trend, all p < 0.001). Combining all genotypes, instrumental variable analysis yielded a genetic relative risk for AVS of 1.6 (95% CI: 1.2 to 2.1) for a 10-fold Lp(a) increase, comparable to the observational hazard ratio of 1.4 (95% CI: 1.2 to 1.7) for a 10-fold increase in Lp(a) plasma levels. CONCLUSIONS Elevated Lp(a) levels and corresponding genotypes were associated with increased risk of AVS in the general population, with levels >90 mg/dl predicting a threefold increased risk.
No takes yet. Share an insight, caveat, or question.
Kamstrup et al. (2013) conducted an observational in Aortic valve stenosis (n=77,680). Elevated Lipoprotein(a) levels vs. Lipoprotein(a) levels <5 mg/dl was evaluated on Aortic valve stenosis (HR 2.9, 95% CI 1.8-4.9, p=<0.001). Elevated Lipoprotein(a) levels >/dl were associated with a nearly threefold increased risk of aortic valve stenosis compared to levels </dl.
Synapse has enriched 10 related papers. Consider them for comparative context: